Page 1246 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1208 ParT TEN Prevention and Therapy of Immunological Diseases

KEY CONCEPTS 10. Jackson SH, Miller GF, Segal BH, et al. IFN-gamma is effective in
reducing infections in the mouse model of chronic granulomatous
B-Cell and T-Cell Depletion Strategies disease (CGD). J Interferon Cytokine Res 2001;21(8):567–73.
11. Ridderstad A, Abedi-Valugerdi M, Möller E. Cytokines in rheumatoid
• Monoclonal antibody (mAb)–mediated depletion of CD20 B lymphocytes arthritis. Ann Med 1991;23(3):219–23.
+
is effective in the treatment of antineutrophil cytoplasmic antibody 12. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and
(ANCA)–associated vasculitis, cryoglobulin syndromes, and rheumatoid meta-analysis of the efficacy and safety of existing TNF blocking agents
arthritis (RA); the best responses in patients with RA are those with in treatment of rheumatoid arthritis. PLoS ONE 2012;7(1):e30275.
significant elevations in rheumatoid factor (RF) and anti–citrullinated
peptide (CCP) antibodies. 13. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr
• There are subsets of T cells that also express CD20, and part of the Opin Rheumatol 2004;16(4):338–43.
clinical efficacy of anti-CD20 mAb reagents may be attributed, in part, 14. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A
to depletion of these subsets of T cells. systematic review. J Rheumatol 2006;33(7):1447.
• mAb reagents with greater binding affinity and binding sites more 15. Li Y, Li A, Strait K, et al. Endogenous TNF-alpha lowers maximum peak
proximate to the cell membrane appear to have greater efficacy bone mass and inhibits osteoblastic Smad activation through NF-κB.
+
depleting CD20 lymphocytes. J Bone Miner Res 2007;22(5):646–55.
• Depletion of CD20 lymphocytes has been associated with reactivation 16. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of
+
of hepatitis B virus (HBV), and vigilance for latent HBV reactivation is tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of
prudent when using anti-CD20 mAb reagents. placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6(6):644.
• mAb reagents targeting CD52 deplete both T-helper cells as well as 17. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma
regulatory T cell (Treg) subsets; imbalances in relative homeostatic gangrenosum responding to infliximab and adalimumab. Br J Dermatol
T-cell reconstitution following treatment may result in autoimmune 2005;152(5):1059–61.
complications. 18. Vallet H, Riviere S, Sanna A, et al; French Behçet Network. Efficacy of
anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter
study of 124 patients. J Autoimmun 2015;62:67–74.
19. Kisacik B, Pamuk ON, Onat AM, et al. Characteristics Predicting
disease Reed-Sternberg cells, BTX-v is presently approved for Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: report
use in the treatment of patients with Hodgkin lymphoma as from a Large Multicenter Cohort with High Background Prevalence.
J Rheumatol 2016;43(3):524–9.
well as of those with refractory non-Hodgkin lymphomas 20. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections
expressing CD30. Enhanced expression of CD30 on CD8 T cells complicating tumor necrosis factor alpha blockade therapy. Mayo Clin
as well increased levels of sCD30 have been observed in patients Proc 2008;83(2):181–94.
with active SLE, and BTX-v is currently being evaluated for 21. Hellgren K, Dreyer L, Arkema EV, et al; ARTIS Study Group, For the
potential clinical efficacy in the management of SLE. 100 DANBIO Study Group. Cancer risk in patients with spondyloarthritis
treated with TNF inhibitors: a collaborative study from the ARTIS and
Please check your eBook at https://expertconsult.inkling.com/ DANBIO registers. Ann Rheum Dis 2016 May 4.
for self-assessment questions. See inside cover for registration 22. Ko JM, Gottlieb AB. Kerbleski JF. Induction and exacerbation of
details. psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
J Dermatol Treat 2009;20(2):100–8.
23. Magnano MD, Robinson WH, Genovese MC. Demyelination and
REFERENCES inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol
2004;S22(5 Suppl. 35):S134–40.
1. Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 24. De Bandt M, Sibilia J, Le Loët X, et al; Club Rhumatismes et
fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. Inflammation. Systemic lupus erythematosus induced by anti-tumour
J Autoimmun 2015;58:48–58. necrosis factor alpha therapy: a French national survey. Arthritis Res
2. von Spee-Mayer C, Siegert E, Abdirama D, et al. Low-dose interleukin-2 Ther 2005;7(3):R545–51.
selectively corrects regulatory T cell defects in patients with systemic 25. Cantaert T, De Rycke L, Mavragani CP, et al. Exposure to nuclear
lupus erythematosus. Ann Rheum Dis 2016;75:1407–15. antigens contributes to the induction of humoral autoimmunity
3. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNα/ribavirin/ during tumour necrosis factor αblockade. Ann Rheum Dis 2009;68(6):
protease inhibitor combination in hepatitis C virus associated mixed 1022–9.
cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 26. Kranich J, Krautler NJ, Heinen E, et al. Follicular dendritic cells control
2014;73(5):831–7. engulfment of apoptotic bodies by secreting Mfge8. J Exp Med
4. Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid 2008;205(6):1293–302.
granulomatosis with Epstein-Barr viral infection of B lymphocytes and 27. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and
response to interferon-alpha 2b. Blood 1996;87(11):4531–7. interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol
5. Park JY, Chung YR, Lee K, et al. Clinical experience of interferon alfa-2a 2008;4(1):34–42.
treatment for refractory uveitis in Behçet’s disease. Yonsei Med J 28. Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute
2015;56(4):1158–62. severe gout in critically ill patients. Semin Arthritis Rheum
6. Kötter I, Hamuryudan V, Oztürk ZE, et al. Interferon therapy in 2015;45(1):81–5.
rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 29. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of
2010;22(3):278–83. systemic juvenile idiopathic arthritis-associated macrophage activation
7. Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. syndrome through treatment with anakinra and corticosteroids. J Clin
Ann Clin Transl Neurol 2014;1(8):622–31. Rheumatol 2011;17(1):23–7.
8. Bonaci-Nikolic B, Jeremic I, Andrejevic S, et al. Anti-double stranded 30. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of
DNA and lupus syndrome induced by interferon-beta therapy in a Anakinra in Refractory Adult-Onset Still’s Disease: Multicenter Study of
patient with multiple sclerosis. Lupus 2009;18(1):78–80. 41 Patients and Literature Review. Medicine (Baltimore)
9. The International Chronic Granulomatous Disease Cooperative Study 2015;94(39):e1554.
Group. A controlled trial of interferon gamma to prevent infection in 31. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor
chronic granulomatous disease. N Engl J Med 1991;324(8):509. Blockade Is Associated With Reduced Mortality in Sepsis Patients With